A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM) | MicrobiomeTrials
A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)
CompletedPHASE2INTERVENTIONAL
Trial Details
Start: 2023-12-04Est. Completion: 2025-07-02
Enrollment target: 12 participants
Locations
Advanced Research Center, Inc., Anaheim, California, United States
Centro Mineiro de Pesquisa - CMiP, Juiz de Fora, Minas Gerais, Brazil
LMK Servicos Medicos SS, Porto Alegre, Rio Grande do Sul, Brazil
Revmatologicky ustav, Prague, Praha, Hlavní Mesto, Czechia
Unidad de Investigacion de las Enfermedades Reumaticas S.A. De C.V., Mexico City, Mexico
Accelerium, S. de R.L. de C.V. - PPDS, Monterrey, Mexico